Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

In a report released today, from Wells Fargo maintained a Hold rating on Alnylam Pharma, with a price target of $256.00. In addition to Wells Fargo...

Alnylam Pharma (ALNY) Gets a Hold from Wells Fargo

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alnylam Pharma today and set a price target of $318.00. According to TipRanks, Matt...

Alnylam Pharma (ALNY) Receives a Buy from Stifel Nicolaus

The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has...

Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks

Jefferies analyst Faisal Khurshid maintained a Hold rating on Alnylam Pharma today and set a price target of $230.00. According to TipRanks, Khursh...

Jefferies Sticks to Their Hold Rating for Alnylam Pharma (ALNY)

Wells Fargo analyst maintained a Hold rating on Alnylam Pharma today and set a price target of $316.00. In addition to Wells Fargo, Alnylam Pharma ...

Alnylam Pharma (ALNY) Receives a Hold from Wells Fargo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Disc Medicine (IRON) and Alnylam Pharma (ALNY) with ...

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Alnylam Pharma (ALNY)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $485.00. Trucch...

H.C. Wainwright Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Ho...

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amneal Pharmaceuticals (AMRX), Alnylam Pharma (ALN...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALNY	$228.65	+0.67%	1.53M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALNY	$228.65	+0.7%	1.53M
3
4
5
6

ALNY

Get Alnylam Pharmaceuticals, Inc. Data in Excel

Get Alnylam Pharmaceuticals, Inc. Data in Excel